Can a simple antibody infusion shield kidney transplants from a sneaky virus?
NCT ID NCT04222023
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving intravenous immunoglobulins (IVIG) could prevent BK virus infection in kidney transplant recipients. The virus often causes graft problems. Researchers enrolled 359 patients with low antibody levels against their donor's virus strain and gave some of them three doses of IVIG after transplant. The goal was to see if this reduced the number of patients with high virus levels in the blood six months later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Intravenous immunoglobulins (IVIG)
- What this could lead to
- If it works, this could provide a way to prevent BK virus infection after kidney transplant, reducing the risk of graft loss.
- What could go wrong
- This is a completed Phase 4 trial, but results are not yet widely reported. The benefit may depend on matching the donor's virus strain, and IVIG can cause side effects like allergic reactions or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, 67000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients
- New Two-Step therapy aims to stop chronic kidney transplant rejection
- Smartphone app and booklet could help kidney transplant patients stick to medications